Press Releases

Press Releases

    Date Title View
    11/04/19
    Summary ToggleNew Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting
    PDF Version
    10/31/19
    Summary ToggleIntegrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life
    PDF Version
    10/24/19
    Summary ToggleHorizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
    PDF Version
    10/24/19
    Summary ToggleNew Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting
    PDF Version
    10/17/19
    Summary ToggleFORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year
    PDF Version
    10/17/19
    Summary ToggleHorizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
    PDF Version
    10/11/19
    Summary ToggleNew Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease
    PDF Version
    10/10/19
    Summary ToggleFor World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”
    PDF Version
    10/09/19
    Summary ToggleHorizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019
    PDF Version
    10/08/19
    Summary ToggleNew Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
    PDF Version
    Displaying 31 - 40 of 496 results